ClinConnect ClinConnect Logo
Search / Trial NCT06496529

ExoDoF: Robotic Exoskeleton for Upper Limb Motor Rehabilitation After Stroke

Launched by UNIVERSITY OF CHILE · Jul 3, 2024

Trial Information

Current as of August 20, 2025

Not yet recruiting

Keywords

Stroke Recovery Motor Recovery Upper Extremity Recovery

ClinConnect Summary

This clinical trial, called ExoDoF, is exploring a new way to help people recover movement in their arms after having a stroke. The researchers want to see if using a robotic exoskeleton, combined with video games, can improve the ability to control arm movements better than traditional therapy. They believe that by limiting certain movements, they can make it easier for patients to regain control and reduce the use of compensatory strategies, which are alternative ways of moving that some people might adopt instead of normal movement.

To be eligible for this study, participants must be between 65 and 74 years old and have had a stroke within the last six weeks that has affected their ability to move their arm. They should also have some level of movement ability, but not too much, as indicated by specific assessments. However, those with serious cognitive issues or other medical conditions that make participation difficult will not be included. Participants can expect to engage in therapy sessions using the robotic exoskeleton and video games, which aim to make rehabilitation more effective and enjoyable. It's important to note that this trial is not yet recruiting participants, so further updates will be provided as the study progresses.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Diagnosis of ischemic or hemorrhagic stroke with zero to six weeks of evolution.
  • Subjects with alterations in active voluntary movement of ES with Fugl Meyer less than or equal to 50 points. Strength of shoulder abduction or finger extension from palpable contraction (1 in Medical Research Council (MRC) scale for muscle strength).
  • Exclusion Criteria:
  • Cognitive impairment that prevents signing the informed consent, following the instructions and understanding the procedures. (MOCA \< 18).
  • Inability to perform activities sitting for more than 90 minutes or inability to perform activities without severe pain (VAS \> 6) or having limited reach ranges.
  • Have severe visual impairment that does not allow to carry out the activities associated with the task.
  • Previous stroke with neurological sequelae in the upper extremity.
  • Present bilateral sensorimotor alterations.
  • Damage to the cerebellum/peduncles described in the radiological report or classic signs of cerebellar damage (Upper extremity SARA items of 2 or more)

About University Of Chile

The University of Chile, a leading academic institution in South America, is dedicated to advancing medical research and improving public health through innovative clinical trials. With a strong emphasis on collaboration among multidisciplinary teams, the university leverages its extensive resources and expertise to conduct rigorous and ethically sound studies. By integrating cutting-edge scientific methodologies and fostering partnerships with healthcare providers, the University of Chile aims to contribute valuable insights to the medical community and enhance patient care both locally and globally.

Locations

Patients applied

0 patients applied

Trial Officials

Pablo Burgos, PhD

Study Director

University of Chile

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported